Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Emavusertib plus Zanubrutinib in B-cell Malignancies
2025-523600-68-00Phase 2Authorised
- Sponsor
- Curis, Inc.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of emavusertib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mature B-cell lymphoma (2 cohorts), sponsored by Curis, Inc. Primary endpoints: Cohort 1: Undetectable measurable residual disease (uMRD) rate and Cohort 2: Overall response rate (ORR). Planned start Mar 2026; status: authorised.
02
Drugs
emavusertib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mature B-cell lymphoma
Beyond the preview
Go deeper on 2025-523600-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523600-68-00.